rare diseases treatment
Scope
Date
~
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals launches uremia itching treatment tablet
SK Chemicals said on Monday that it has launched Remitch in orally disintegrating tablets, a treatment for intractable uremic pruritus (uremia itchi...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Biomedics gets approval for Parkinson's disease clinical trials
South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clin...
Jan 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N gets approval to sell K-CAB in Singapore
South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biopharma attains patent for solid cancer treatment antibody
Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Kolon signs MOU with Hanyang Univ. to develop gene therapy treatments
Kolon Industries Inc.'s Future Technology Institute said on Thursday that it had signed a memorandum of understanding with the Hanyang University In...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
NeoImmuneTech, US think tank to develop treatment for acute radiation syndrome
Biopharmaceutical company NeoImmuneTech has grabbed an opportunity to supply new drug candidates in development as strategic items to the US gover...
Jan 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Supply chain
South Korea to double stockpiles of rare-earth minerals
South Korea's Ministry of Trade, Industry and Energy said on Friday it will double the government's stockpiles of rare-earth minerals and halve thei...
Dec 30, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CENYX Biotech, developing treatment for brain damage with ROS-scavenging, nano-sized heavy metals
When severe brain diseases such as cerebral infarction or cerebral hemorrhage occur, the blood-brain barrier (BBB) in our body no longer functions p...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
ToolGen, ANLBIO to jointly develop progeria treatments
South Korea's two biotech startups ToolGen Incorporated and ANLBIO on Tuesday signed a joint research and development agreement for developing proge...
Dec 21, 2022 (Gmt+09:00)
-
Bio & Pharma
Bigsome Bio signs tech transfer agreement with university
Bigsome Bio, a subsidiary of Lotte Chilsung Beverage, has begun research on functional materials for respiratory health.The company said on Friday t...
Dec 20, 2022 (Gmt+09:00)
-
Bio & Pharma
JW Pharma applies for phase 3 trial in Taiwan for gout treatment
JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, w...
Dec 19, 2022 (Gmt+09:00)
-
Companies
SK Materials, Arencibia ink MOU on noble gas recycling
SK Materials Airplus Co. announced on Monday that it signed an MOU with US-based Arencibia to prepare to enter the noble gas recycling business.&n...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials
LG Chem Ltd. announced in a disclosure on Monday that it had confirmed superior efficacy in phase 3 clinical trials for the combined administration ...
Dec 13, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biotech firm Noul signs MOU with disease center of Ghana
South Korea's Medical diagnostics company Noul Co., Ltd. said on Monday that it has signed a memorandum of understanding with the Ghana Infectious D...
Dec 12, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ partners with Emmyon to develop ingredients preventing muscle atrophy
South Korean food giant CJ CheilJedang Corp. announced on Tuesday that it has signed a license contract with Emmyon, an American biotechnology start...
Dec 06, 2022 (Gmt+09:00)
-
Bio & Pharma
Orion to enter dental disease treatment sector
Orion Corp., the Korean company, best known for its signature product choco pie, is entering drug development. Instead of indirectly running a joint...
Nov 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Waste management
BKT thrives as lone Korean wastewater treatment provider in US
South Korean water treatment provider Bukang Tech(BKT) on Wednesday said it earned a contract to build a wastewater treatment facility in the US sta...
Nov 18, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharma's epilepsy treatment posts impressive growth in US
South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...
Nov 11, 2022 (Gmt+09:00)
-
Companies
US water treatment juggernaut Culligan eyes Chungho Nais stake
Culligan, the biggest water treatment company in the United States, is set to become a major shareholder in South Korean water purifier rental firm ...
Nov 09, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand